Skip to main content
Erschienen in: Journal of Interventional Cardiac Electrophysiology 3/2020

17.04.2019

Improvement in the quality of life of patients with persistent or long-standing persistent atrial fibrillation after hybrid ablation

verfasst von: Pavel Osmancik, Petr Budera, David Talavera, Dalibor Herman, Jana Vesela, Radka Prochazkova, Vitalii Rizov, Petr Kacer

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Hybrid ablation (i.e., a combination of a thoracoscopic surgical ablation followed by a catheter ablation) is a treatment option for patients with non-paroxysmal atrial fibrillation (AF). Despite its promising efficacy, it is a surgical procedure with a relatively high risk of complications that could affect the quality of life (QoL) of patients, even when sinus rhythm is restored.

Objective

To describe changes in the QoL of patients with non-paroxysmal AF before and after a hybrid ablation.

Methods

Patients after hybrid ablation for persistent or long-standing persistent AF were prospectively studied. Follow-up visits were scheduled at 1, 3, 6, 9, and 12 months. The maintenance of SR was assessed using 1-week Holter recordings at 6 and 12 months and 24-h Holter recordings at 3 and 9 months, or via an implantable loop recorder. QoL was assessed using the Atrial Fibrillation Effect on Quality-of-life (AFEQT) and the EuroQoL-5Dimensions (EQ-5D) questionnaires before and 12 months after ablation.

Results

Seventy-five patients (49 men, age 62.9 ± 8.45 years, 48 (64%) with long-standing persistent AF) were enrolled. Fifty-two (69.3%, SR group) were AF-free during the 12-month follow-up, 16 (21.3%, PAROX group) had only paroxysms of AF after ablation, and 7 (9.3%, PERM group) were on rate control due to permanent AF reoccurrence. The AFEQT score increased significantly in the SR group from 59.9 ± 19.4 to 91.4 ± 10.8 (p < 0.001), and in the PAROX group from 58.8 ± 19.0 to 81.5 ± 14.1 (p = 0.002) but remained unchanged in the PERM group (44.6 ± 7.5 vs. 47.4 ± 5.5, p = 0.24). The EQ-5D score significantly decreased in the descriptive part (from 7.90 ± 2.61 to 6.64 ± 1.90, p = 0.0001) and increased on the visual analog scale (from 63.56 ± 19.11 to 79.30 ± 16.9, p < 0.0001) in the SR group. In the PAROX group, no significant change was present on either the descriptive part (p = 0.3) or in the visual analog scale (p = 0.48). Similarly, no significant changes were present on either the descriptive part (p = 0.93) or the visual analog scale (p = 0.4) in the PERM group.

Conclusion

The QoL of patients with non-paroxysmal AF and patients with AF paroxysms, after successful hybrid ablation, improved significantly in patients with SR. No significant improvement was present in patients on rate control after an unsuccessful ablation.
Literatur
1.
Zurück zum Zitat Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370–5.CrossRef Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370–5.CrossRef
2.
Zurück zum Zitat Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119:448 e1–19.CrossRef Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119:448 e1–19.CrossRef
3.
Zurück zum Zitat Walfridsson H, Walfridsson U, Nielsen JC, Johannessen A, Raatikainen P, Janzon M, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden. The MANTRA-PAF trial. Europace. 2015;17:215–21.CrossRef Walfridsson H, Walfridsson U, Nielsen JC, Johannessen A, Raatikainen P, Janzon M, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden. The MANTRA-PAF trial. Europace. 2015;17:215–21.CrossRef
4.
Zurück zum Zitat Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378:417–27.CrossRef Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378:417–27.CrossRef
5.
Zurück zum Zitat Osmancik P, Budera P, Zdarska J, Herman D, Petr R, Straka Z. Electrophysiological findings after surgical thoracoscopic atrial fibrillation ablation. Heart Rhythm. 2016;13:1246–52.CrossRef Osmancik P, Budera P, Zdarska J, Herman D, Petr R, Straka Z. Electrophysiological findings after surgical thoracoscopic atrial fibrillation ablation. Heart Rhythm. 2016;13:1246–52.CrossRef
6.
Zurück zum Zitat Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012;14:528–606.CrossRef Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012;14:528–606.CrossRef
7.
Zurück zum Zitat Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol group. Ann Med. 2001;33:337–43.CrossRef Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol group. Ann Med. 2001;33:337–43.CrossRef
8.
Zurück zum Zitat Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, et al. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2011;4:15–25.CrossRef Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, et al. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2011;4:15–25.CrossRef
9.
Zurück zum Zitat Wokhlu A, Monahan KH, Hodge DO, Asirvatham SJ, Friedman PA, Munger TM, et al. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J Am Coll Cardiol. 2010;55:2308–16.CrossRef Wokhlu A, Monahan KH, Hodge DO, Asirvatham SJ, Friedman PA, Munger TM, et al. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J Am Coll Cardiol. 2010;55:2308–16.CrossRef
10.
Zurück zum Zitat Fiala M, Wichterle D, Bulkova V, Sknouril L, Nevralova R, Toman O, et al. A prospective evaluation of haemodynamics, functional status, and quality of life after radiofrequency catheter ablation of long-standing persistent atrial fibrillation. Europace. 2014;16:15–25.CrossRef Fiala M, Wichterle D, Bulkova V, Sknouril L, Nevralova R, Toman O, et al. A prospective evaluation of haemodynamics, functional status, and quality of life after radiofrequency catheter ablation of long-standing persistent atrial fibrillation. Europace. 2014;16:15–25.CrossRef
11.
Zurück zum Zitat Yagishita A, Yamauchi Y, Sato H, Yamashita S, Hirao T, Miyamoto T, et al. Improvement in the quality of life and exercise performance in relation to the plasma B-type natriuretic peptide level after catheter ablation in patients with asymptomatic persistent atrial fibrillation. Circ J. 2017;81:444–9.CrossRef Yagishita A, Yamauchi Y, Sato H, Yamashita S, Hirao T, Miyamoto T, et al. Improvement in the quality of life and exercise performance in relation to the plasma B-type natriuretic peptide level after catheter ablation in patients with asymptomatic persistent atrial fibrillation. Circ J. 2017;81:444–9.CrossRef
12.
Zurück zum Zitat Bagge L, Blomstrom P, Nilsson L, Einarsson GM, Jideus L, Blomstrom-Lundqvist C. Epicardial off-pump pulmonary vein isolation and vagal denervation improve long-term outcome and quality of life in patients with atrial fibrillation. J Thorac Cardiovasc Surg. 2009;137:1265–71.CrossRef Bagge L, Blomstrom P, Nilsson L, Einarsson GM, Jideus L, Blomstrom-Lundqvist C. Epicardial off-pump pulmonary vein isolation and vagal denervation improve long-term outcome and quality of life in patients with atrial fibrillation. J Thorac Cardiovasc Surg. 2009;137:1265–71.CrossRef
13.
Zurück zum Zitat Kim YG, Shim J, Choi JI, Kim YH. Radiofrequency catheter ablation improves the quality of life measured with a short form-36 questionnaire in atrial fibrillation patients: a systematic review and meta-analysis. PLoS One. 2016;11:e0163755.CrossRef Kim YG, Shim J, Choi JI, Kim YH. Radiofrequency catheter ablation improves the quality of life measured with a short form-36 questionnaire in atrial fibrillation patients: a systematic review and meta-analysis. PLoS One. 2016;11:e0163755.CrossRef
14.
Zurück zum Zitat Ozeke O, Cay S, Ozcan F, Baser K, Topaloglu S, Aras D. Similarities between the renal artery and pulmonary vein denervation trials: do we have to use sham procedures for atrial fibrillation catheter ablation trials? Int J Cardiol. 2016;211:55–7.CrossRef Ozeke O, Cay S, Ozcan F, Baser K, Topaloglu S, Aras D. Similarities between the renal artery and pulmonary vein denervation trials: do we have to use sham procedures for atrial fibrillation catheter ablation trials? Int J Cardiol. 2016;211:55–7.CrossRef
Metadaten
Titel
Improvement in the quality of life of patients with persistent or long-standing persistent atrial fibrillation after hybrid ablation
verfasst von
Pavel Osmancik
Petr Budera
David Talavera
Dalibor Herman
Jana Vesela
Radka Prochazkova
Vitalii Rizov
Petr Kacer
Publikationsdatum
17.04.2019
Verlag
Springer US
Erschienen in
Journal of Interventional Cardiac Electrophysiology / Ausgabe 3/2020
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-019-00546-7

Weitere Artikel der Ausgabe 3/2020

Journal of Interventional Cardiac Electrophysiology 3/2020 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.